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Abstract 
Background 
Somatic mutations in cancer cells affect various genomic elements disrupting important 
cell functions. In particular, mutations in DNA binding sites recognized by transcription 
factors can alter regulator binding affinities and expression of target genes. A number 
of promoter mutations have been linked with an increased risk of cancer, mutations in 
binding sites of selected transcription factors have been found under positive selection. 
However, negative selection of mutations in coding regions is elusive and significance 
of negative selection in non-coding regions remains controversial. 
Results 
Here we present analysis of transcription factors with binding sites co-localized with 
non-coding variants. To avoid statistical bias we account for mutation signatures of 
different cancer types. For many transcription factors, including multiple members of 
FOX, HOX, and NR families, we show that human cancers accumulate fewer mutations 
than expected by chance that increase or decrease affinity of binding motifs. Such 
conservation of motifs is even more exhibited in DNase accessible regions. 
Conclusions 
Our data demonstrate negative selection against binding sites alterations and suggest 
that this selection pressure protects cancer cells from rewiring of regulatory circuits. 
Further analysis of transcription factors and the respective conserved binding motifs can 
reveal cell regulatory pathways crucial for the survivability of various human cancers. 
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Background 
Somatic mutations in DNA binding sites recognized by transcription factors [1, 2] can 
alter regulator binding affinities and expression of the target genes [3], often leading to 
malignant cell transformation. Affinity change can be directly associated with cancer 
progression with a striking example of a GABP (ETS-family factor) binding site emerging 
in TERT promoter [4] associated with progression of different tumor types [5, 6]. A 
number of other promoter mutations have been linked with an increased risk of cancer 
[7, 8], and the number is expected to grow rapidly with extensive sequencing of 
complete cancer genomes. For instance, in the recent study of regions associated with a 
risk of epithelial ovarian cancer [9] out of nearly three hundreds significant SNPs only 
two were found in protein coding regions, whereas 25 such SNPs were localized in 
transcription factor binding sites. 
Likewise, cancer drivers identified in knockdown experiments [10] not necessarily carry 
mutations in coding regions, thus underlining the importance of regulatory mutations 
modifying gene expression. 
Frequencies of synonymous and non-synonymous substitutions allow studying 
selection of cancer somatic mutations in protein-coding regions [11]. For non-coding 
regions estimates of selection pressure can be based on functional annotation of 
sequence variants. In particular, DNA sequence motifs [12] recognized by the 
transcription factors usually have strict and degenerate positions. This allows assessing 
selection of sequence variants in binding sites in a way resembling usage of non-
synonymous and synonymous substitutions in codons. 
Somatic mutations often tend to destroy binding sites [3, 13] of specific 
transcription factors reflecting positive selection of variants. Conversely, binding sites of 
other transcription factors were reported to avoid mutational changes [13], but the 
significance of negative selection pressure acting at somatic mutations remains 
controversial [3, 13].  
Mutations in cancer cell lineages are strongly context-dependent [14]; thus, 
mutation signatures of different cancer types should be properly taken into account to 
avoid statistical bias.  Here, we used genome wide data [14] on several cancer types 
with different mutation signatures to study the frequencies of somatic mutations that 
alter binding sites for specific transcription factors. 
Results 
Assessing selection pressure on transcription factor binding sites 
To study selection pressure on gene regulatory regions we used mutation sets from 
different cancer samples grouped by the tissue [14]. First, we selected mutations in 
putative regulatory regions (intronic and promoter genomic segments) which made up 
to 50% of total mutation calls (Additional file 3: Supplementary Table 1). Then, we 
mapped transcription factor binding sites [15] in small windows centered at the 
mutation sites (see Methods, predicted binding sites were allowed to be located in the 
vicinity of but not necessarily overlap the mutated base). For a particular tested motif, 
on average 5 ± 3% of tested windows included binding sites predictions, but there were 
exceptional cases with notably deviating prediction rates (see Additional file 4: 
Supplementary Table 2 for complete data). 
Putative affinity changes were estimated for the mutated allele versus the 
germline [16]. We separately considered both directions of affinity change that can be 
caused by a nucleotide substitution in a binding site: affinity loss (disruption of a 
binding site predicted for the germline allele) and affinity gain (improvement or 
emergence of a binding site with stronger prediction for the mutated allele). 
To evaluate the selection pressure we compared the observed frequency of 
mutations substantially changing the binding site affinity with the expected frequency 
estimated from simulated control data. 
We used two different control data sets: (1) the shuffle control consisting of 
sequences with randomly shuffled nucleotides around the actual mutated bases, similar 
to that in previous studies [3] but controlling the mutation context (the germline and 
mutated nucleotides and the proximal 5' and 3' nucleotides); and (2) the genomic 
control consisting of randomly sampled segments of promoter and intronic regions not 
overlapping the mutation-centered windows (see Methods for details). 
To account for specific mutation signatures of different cancer types (see 
Additional file 1: Supplementary Figure 1), binding sites predictions in both shuffle and 
genomic controls were sampled to equalize the resulting distribution of mutation 
contexts of a given control data to match the cancer mutations data, separately for each 
cancer type. 
Finally, we identified binding motifs exhibiting an exceptional rate of mutation-
induced affinity changes versus both control data sets with equalized contexts 
distribution (FDR-corrected two-tail Fisher's P < 0.05, see Additional files 4-5: 
Supplementary Table 2-3 for complete data, see Methods for details).  
Limited magnitude of selection pressure requires high statistical power 
For each transcription factor binding motif we estimated magnitude of selection 
pressure on somatic mutations overlapping the predicted binding sites. The selection 
pressure magnitude was defined as the ratio of the observed and expected frequencies 
of mutation-induced affinity changes assessed for the somatic mutations (observed) and 
the simulated control data (expected), respectively (see Methods). The typical values of 
the selection pressure magnitude were around 0.9-0.95 (negative selection) and 1.05-
1.1 (positive selection, see Figure 1) and were in a similar range for mutations causing 
affinity gain and affinity loss. 
With ratios expressing selection pressure magnitude so close to 1, a large data 
volume was necessary to attain acceptable statistical significance. In particular, the 
simulated control sets were several times larger than the initial cancer data set, 
especially for cancer types with less called mutations. The most robust observations 
were made on cancer types with the highest mutation counts and thousands to dozens 
of thousands predictions per binding motif (see Additional file 4: Supplementary Table 
2).  
Negative selection of mutations altering binding motif affinity 
Among transcription factors with binding sites experiencing frequent affinity loss we 
observed those belonging to AP-2 and C/EBP families, whose binding motifs were 
previously reported as mutation-enriched [3, 13]. Binding motifs of zinc finger SP and 
KLF families were also enriched with affinity loss-causing mutations in several cancer 
types. Mutations in binding sites of other transcription factors, in particular, ETS family 
motifs, persistently induced affinity gain (see Table 1 and Additional file 4-5: 
Supplementary Table 2-3). Binding motifs enriched with mutations causing affinity loss 
or affinity gain are likely to be under positive selection.  
Conversely, for a much wider set of transcription factor binding motifs, 
mutations leading to either affinity gain or affinity loss were depleted (Table 1, 
Additional file 4-5: Supplementary Table 2,3). Furthermore, for some factors binding 
motifs were simultaneously protected from both affinity loss and gain in several cancer 
types. In particular, there were several families of nuclear receptors (Figure 2, TFClass 
families [17] are shown). Such conserved binding motifs indicate action of negative 
selection against somatic mutations. Importantly, negative selection of HOX and FOX 
motif-changing variants, that was reported earlier for normal tissues [18], was also 
exhibited for mutations in different cancers. 
Only a few binding motifs were found significant for cancer types with limited 
number of available mutation calls due to lower statistical power. However, these 
orphan motifs often belonged to the families found under systematic protection from 
the affinity loss or gain in larger data sets (Additional file 5: Supplementary Table 3). 
Stronger negative selection acts in DNase accessible regions 
Accuracy of binding sites prediction in silico is limited and it is hard to distinguish true 
binding sites from false positive predictions without direct experimental data. To 
increase the confidence of binding site prediction, we considered subsets of mutations 
occurring in DNase accessible segments [19] of promoters and introns for breast cancer 
and lung adenocarcinoma.  
Mutation rates can unpredictably depend on chromatin accessibility. Hence, a 
separate control set constructed from DNase accessible regions was necessary to 
evaluate selection of mutations in DNase accessible regions. The resulting estimates of 
the selection pressure magnitude became comparable with those for the whole set of 
mutations in promoter and intronic segments. 
A smaller absolute number of mutations in DNase accessible regions resulted in 
a lower number of binding sites predictions and a lower statistical power (Additional 
file 6: Supplementary Table 4), thus the absolute number of featured binding motifs was 
also smaller. However, the major observations persisted. In particular, motifs of FOX 
and several NR families were found protected from somatic mutations whereas selected 
members of AP-2 and C/EBP families displayed persistent affinity loss. 
Taking the motifs found under significant negative selection for the full set of 
intronic+promoter mutations (P-value < 0.05 for a particular control), we compared the 
estimates of the selection pressure magnitude with those for mutations in the DNase 
accessible regions.  While there were no systematic difference for the shuffle control, 
the genomic control revealed consistently lower relative frequency of the affinity 
changing events (i.e. stronger selection magnitude) for the most of significant motifs in 
DNase accessible regions (Figure 3). We believe this is a strong indication of the 
increased negative selection pressure on DNase accessible regions. The magnitude of 
positive selection in DNase accessible regions was lower (closer to 1), and the number 
of motifs detected under positive selection was lower (Additional file 6: Supplementary 
Table 4). 
  
Discussion 
Similar binding motifs are under similar selection pressure 
Transcription factors of a given structural family [17] usually share similar binding 
preferences and it is not always possible to distinguish binding sites bound by different 
members of the same family. In particular, attribution of binding predictions to a 
particular transcription factor is not entirely reliable, that is why focused on 
observations that were consistent for different members of a given motif family. 
Furthermore, the similarity of binding motifs of the same family made it less likely that 
the observed statistical preferences of mutations to alter or avoid predicted binding 
sites appeared from biased predictions of a particular low-quality binding model. 
Transcription factors of the same family often had binding motifs obtained from 
different experimental data sets [15] and thus had different prediction biases. 
Consistency between several motifs belonging to transcription factors of the same 
family increased our confidence that the detected selection pressure was indeed related 
to binding sites. 
Genomic control data highlight negative selection 
We emphasize the usage of genomic control in addition to shuffle control, since 
genomic sequences prefer or avoid occurrences of sequence motifs in a non-random 
fashion. For instance, composition of CpG islands correlates with the presence of many 
Kruppel-like transcription factor motifs, whereas nucleosome binding motifs facilitate 
binding of TBP factor [20]. All these regularities are destroyed in shuffle control. 
In general, genomic control gave more conservative estimates of selection 
magnitude (Figure 1) but there was a notable overlap between the resulting sets of 
motifs (Additional file 2: Supplementary Figure 2) identified in comparison with any of 
the two controls, especially for the motifs conserved by negative selection. However, for 
positive selection the overlap was quite limited. For example, binding sites of HIF-1 
transcription factor were found under strong positive selection both for affinity gain and 
affinity loss when the shuffle control was used, but the effect completely disappeared 
with the genomic control (Additional file 4: Supplementary Table 2). Such observations 
are not easy to interpret, so in our analysis we focused on cases, which were consistent 
(with the same selection direction) and significant (P < 0.05) for both control data sets. 
Many transcription factors with binding sites under selection have been 
reported to be involved in cell malignant transformation. For instance, we detected 
significant enrichment of affinity gain events for C/EBP that was reported to be 
important for malignant conversion of human breast epithelial cells [21]. Binding sites 
of GABP, a member of ETS family, are created by mutations in TERT promoter and 
associated with development of many cancer types [4]. In our study the affinity gain of 
ETS binding sites appeared under positive selection, whereas affinity loss under 
negative selection. FOX proteins, whose binding sites were found under negative 
selection both for affinity gain and loss, were also suggested to be involved in cancer 
progression [22]. 
To summarize our findings, we observed transcription factor binding sites of 
many motif families in several cancer types altered by somatic mutations significantly 
less frequently than expected, both for mutations causing affinity loss or gain. The 
avoidance of mutations in binding motifs indicated the action of negative selection 
maintaining specific paths in cellular regulatory circuits. This observed negative 
selection of mutations leading to substantial affinity gain rejects a possible alternative 
explanation that the observed difference is caused by transcription factors providing the 
protection against mutations at binding sites by occupying respective DNA segments. 
Another alternative explanation, that the observed statistical phenomena arise from 
biased mutation patterns of a particular cancer type, can be ruled out because 
conserved binding motifs are shared in cancers with substantially different mutation 
signatures (see Additional file 3: Supplementary Table 1 and Additional file 1: 
Supplementary Figure 1). 
Finally, the conservation of binding motifs against mutations was exhibited 
even in a simple test considering how often mutations occupied positions within the 
motifs versus nearby positions in the vicinity (see Methods and Additional file 7: 
Supplementary Table 5). The resulting list of motifs was less selective and harder to 
interpret since the substitution itself and affinity change direction were not considered. 
However, major families of motifs that tended to overlap/avoid mutations (i.e. with 
more/less mutations within motifs than expected) were consistent with the detailed 
affinity change test, in particular, including members of ETS, AP-2 and FOX, HOX 
families overlapping and avoiding mutations, respectively. 
Further analysis of factors with binding motifs protected by negative selection 
against mutations can reveal cell regulatory pathways crucial for the survivability of 
various human cancers. 
  
Methods 
Overview of cancer mutations data 
We used published whole genome somatic mutations data for ten cancer types [14] 
(507 samples with varying sequencing depth) with mutations from different samples of 
the same cancer type aggregated. The total number of mutation calls varied between 
cancer types with breast cancer, liver cancer and lung adenocarcinoma having the 
largest numbers (Additional file 3: Supplementary Table 1). Only single-nucleotide 
substitutions were considered.  
Ensembl gene annotation was used to select mutations in [-5000;+500] bp 
intervals from transcription start sites (promoters) and intronic regions. The length of 
considered intronic and promoter segments totaled 1,6⋅109 bps with an average 
mutations density of 1-2 substitutions per 5 kb for the cancers with the highest number 
of mutation calls. 
Mutations in coding regions were excluded. An overview of the initial mutation 
data is given in Additional file 3: Supplementary Table 1. The relative frequencies of 
mutation contexts (the 5' and 3' nucleotides surrounding the mutated/germline alleles) 
are shown in Additional file 1: Supplementary Figure 1. 
The mutation coordinates were used to extract mutation-centered [-50; +50] bp 
genomic windows based on Ensembl GRCh37.p13 (release 75) genome assembly. 
Overlapping windows for closely located mutations were considered independently 
(thus a single binding site in theory could be assessed for more than one mutation). 
Within a single cancer sample some windows with different mutation coordinates had 
identical sequences (e.g. due to genomic repeats), and, for each particular sample, only 
one of these windows was kept for further analysis. Recurrent mutations in different 
samples were considered as independent observations. The statistical analysis (see 
below) was performed separately for each cancer type. 
Assessing binding motif affinity changes 
DNA motifs recognized by transcription factors are highly divergent. A basic binding site 
model, position weight matrix (PWM), accounts for such divergence by assigning a score 
for each oligonucleotide of some fixed length, with high scoring sequences selected as 
binding sites. A fixed score threshold defines the positive prediction rate (motif P-value) 
for the given PWM. With a uniform distribution of background frequencies the motif P-
value is equal to the fraction of oligonucleotides (“words”) scoring above the given 
threshold among all words of the fixed length. For a given sequence variant the score of 
the best binding site prediction defines the respective motif P-value. In annotation of 
regulatory SNPs the ratio of motif P-values for two sequence variants was used to 
quantify the effects of nucleotide substitutions in predicted binding sites [23, 24]. 
The correspondence between the motif P-value and the energy of specific 
binding (the so-called discriminative energy) is clarified in the classic work of [25]. It is 
shown that for a point substitution in a binding motif the log-ratio of P-values defined 
by two alternative sequence variants is approximately equal to the difference of 
corresponding discriminative energies. We defined substantial difference as the drop in 
the discriminative energy that increases the motif P-value four fold, which corresponds 
to the substitution of a perfectly nondegenerate position to a completely degenerate 
position in an imaginary model that did not contain any degenerate positions. 
To predict the binding sites and to quantify affinity change events we used 
PERFECTOS-APE software [16]. Binding sites were predicted in [-50;+50] bp mutation-
centered windows as best hits of 278 A/B/C-quality (highest quality) PWMs from the 
HOCOMOCO [15] collection. The closest position of a binding site was required to be 
located not farther than 11 bp (one helix pitch) away from the mutated base. This setup 
allowed us to bypass global variability in mutational rates which may induce an 
unknown bias in co-localization of mutations with binding motifs. To avoid such 
conditioning by genome location preferences we predicted binding sites only in small 
windows centered at mutations, thus considering only regions containing both a 
binding site and a somatic mutation.   
For predictions we used the motif P-value threshold of 0.0005 (which roughly 
defines a false positive rate with a single expected prediction per 1000bp of random 
double stranded sequence). The approach to take PWM score thresholds according to a 
common false positive rate was recently demonstrated to be the least biased in a 
comparative study [26].  
It is not trivial to truly assess the quality of binding site prediction since very 
little is known on the negative control, the DNA sequences that do not bind a particular 
transcription factor. For example, FoxA2 has well-exhibited binding preferences and has 
been tested for false-positive predictions in [27] with the help of EMSA experiments. 
For the HOCOMOCO model at 0.0005 P-value the resulting experimentally-justified FDR 
was about 17% providing an intuition on binding site prediction error rate. Yet, since 
only 64 hand-picked binding sites (41 positive and 23 negative) were checked with 
EMSA this FDR value cannot be used in any quantitative estimation. 
We used the P-value ratio thresholds of 4 (affinity gain, motif emergence) and 
0.25 (affinity loss, motif disruption) to distinguish between substantial and non-
substantial binding site alterations. This setup was identical for each particular cancer 
type (to estimate the observed affinity change frequencies) and control data (to 
estimate expected frequencies). 
To sum up, for a given transcription factor binding motif for a given mutation-
centered window an affinity loss event was counted if (1) the best prediction for the 
germline sequence passed motif P-value of 0.0005 considering PWM hits not farther 
than 11bp away from the mutated base and (2) the best prediction for the mutated 
allele, again, considering PWM hits not farther than 11bp away from the mutated base, 
had P-value at least 4 times weaker. Symmetrically, an affinity gain event was counted 
under the same restrictions for the best PWM hit but for the sequence with the mutated 
allele, and with the respective P-value for the germline sequence predictions being 4 
times weaker. 
We did not require the best hits in the germline and the mutant sequence to 
appear at the same position. Thus, with our approach we did not counted affinity 
change events in windows with two good motif hits, only one of which was affected by 
the mutation. 
Simulated control data 
Two simulated control sequence sets, the shuffle control and genomic control, were 
used to estimate the expected frequency of affinity changing substitutions. The relative 
size of the simulated control sets depended on the total number of mutation calls in a 
particular cancer type. Lower relative size of the control data sets was used for the 
larger mutation sets (see Additional file 3: Supplementary Table 1). Higher relative size 
of the control data sets was used for the cancers with lower numbers of mutation calls 
to provide stable estimates of expected frequencies. 
The shuffle control set was obtained by shuffling the flanking sequences within  
[-50;+50] bp around the mutated base keeping the mutation context, the immediate 5' 
and 3' nucleotides, and the substitution itself, intact. Multiple shuffles were gathered 
for each mutation (Additional file 3: Supplementary Table 1). This was the only step 
where the window length was explicitly used. 
The windows for the genomic control were sampled from intronic and promoter 
regions in a way that they did not overlap the cancer mutation-centered windows. Each 
segment of [-50;+50] bp had the central base and its neighboring 5' and 3' nucleotides 
identical to the mutation context of a given somatic mutation locus, the respective 
nucleotide alternative was added. For each somatic mutation several genomic control 
windows were extracted, the number depended on the total number of mutations for a 
particular cancer type (Additional file 3: Supplementary Table 1). 
Both the shuffle and genomic controls were used to predict transcription factor 
binding sites in the same way as for the cancer data. For each binding motif the 
windows with binding sites predictions for the germline alleles were used to evaluate 
statistical significance of the affinity loss. Likewise, the windows with binding sites 
predicted for the mutated alleles were used to evaluate statistical significance of the 
affinity gain. The windows with predictions for both alleles participated in both types of 
analysis (Figure 4), and the windows without predictions were discarded. 
Since binding sites predictions depended on the nucleotide composition and, 
consequently, on the mutation contexts (the 5’ and 3’ nucleotides proximal to the 
mutated base), we equalized the mutation contexts distributions of the test and control 
data for each particular cancer type before the statistical evaluation (see below). To 
achieve this, we sampled the windows with binding sites predictions in control data 
(both shuffle and genomic) to match a given cancer data for each binding motif 
separately. 
In a limited number of cases there were not enough control data to completely 
equalize the contexts distribution (see Additional file 4: Supplementary Table 2). Yet, 
even for cancer types with low number of mutation calls, where the relative required 
size of the control data sets was extremely large, no less than 95% of predictions with 
matching contexts were successfully sampled from the control data. Importantly, for 
cancer types with abundant mutation calls context equalization was almost perfect 
(99.9-100% match of the contexts distributions with the non-perfect match only for 
exceptional motifs, see Additional file 4: Supplementary Table 2), since a lower relative 
size of the control data set was generally required (see Additional file 3: Supplementary 
Table 1). During significance evaluation (see below) the "missing" control predictions 
were considered as those making the contingency tables more uniform (i.e. reducing the 
difference and its possible statistical significance). 
Thus, for each binding motif we obtained the final sets of mutation-centered 
windows with binding sites overlapping with or located in the close vicinity of 
mutations for test and control data with an equalized mutation contexts distribution. 
This eliminated possible bias from the non-randomness of mutational signatures and 
made possible a comparison of the binding sites alteration frequencies in cancer versus 
control data. 
The events of mutation-induced motif changes were counted for each cancer 
type and the control data sets (shuffle and genomic) using the same procedure. For each 
binding motif the Fisher's exact test was computed using 2x2 contingency tables 
(substantial affinity loss or gain versus non-substantial affinity change/no change, 
cancer mutations versus the control data, separately for shuffle and genomic control), 
refer to Figure 4 for a scheme.  
Only cases that passed 0.05 FDR-corrected (for 278 tested binding motifs) 
Fisher’s exact test P-value in both comparisons (versus the shuffle and versus genomic 
controls) were considered significant for a particular cancer type. 
Estimating the selection magnitude 
The affinity loss frequency was calculated as the fraction of affinity loss events out of 
all tested windows with legitimate motif predictions for the germline allele (see the 
previous section). Symmetrically, the affinity gain frequency was calculated as the 
fraction of with affinity gain events among all windows with legitimate predictions for 
the mutated allele.  
The absolute values of the affinity loss and gain event frequencies are biased 
by the specific mutation signature of each particular cancer type. To account for this 
effect, we computed the relative values normalizing cancer frequencies for those of the 
control data. The ratio of the affinity loss (gain) frequency for cancer somatic mutations 
to the affinity loss (gain) frequency in the control set (genomic or shuffle) defined the 
selection magnitude for affinity loss (gain). The magnitude greater than 1 corresponded 
to the positive selection, the magnitude less than 1 corresponded to the negative 
selection. 
Assessing mutations in DNase accessible segments 
As an additional test, we considered DNase accessible segments of all introns and 
promoters. The DNase accessibility data (breast cancer and lung adenocarcinoma only) 
were collected for related cell lines and normal tissues [28] (Additional file 6: 
Supplementary Table 4). The resulting reduced set consisted of 104905 (596253) 
mutations for breast cancer (lung adenocarcinoma) thus including nearly 30% (90%) 
from the respective total sets of intronic and promoter mutations.  
Open chromatin regions are enriched with binding sites of the most of 
transcription factors but depleted of others [19]. To account for this non-randomness, 
the shuffle and the genomic controls were produced with the same pipeline as for the 
total set of promoter+intronic mutations but restricted to DNase accessible regions only. 
A simplified test to reveal selection pressure 
We also tested a basic overlap of mutations and motifs not taking into account the 
affinity change. To this end we used  2x2 contingency tables for the test / control data 
and mutations overlapping / not overlapping with the motifs (Additional file 7: 
Supplementary Table 5) with the binding sites predictions performed using the same 
setup as in the main workflow. On the one hand, this simplified test did not capture 
neutral substitutions within the motifs and did not allow separating affinity loss and 
gain events. On the other hand, the results of this test did not depend on arbitrary 
selected motif P-value ratio thresholds. 
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 Figure 1. Selection magnitude for affinity loss and gain of ETS, FOX and C/EBP motifs in 
different cancer types. 
X-axis displays the selection magnitude for motif affinity loss (A) or gain (B) caused by 
somatic mutations. Box-plots are provided for ETS-related (14 motifs), FOX (13 motifs), 
C/EBP-related (9 motifs) and NR3 (Steroid hormone receptors, 11 motifs) transcription 
factor families in three cancer types with the largest numbers of mutation calls. In 
particular, C/EBP motifs display frequent affinity loss in breast cancer, FOX and NR3 
motifs are protected from both the affinity loss and gain in lung adenocarcinoma and 
breast cancer, and ETS motifs tend to emerge in all three cancer types (breast, lung and 
liver). Data for two control datasets (shuffle, genomic) are shown. 
 Figure 2. Transcription factor binding motifs protected from somatic mutations in different 
cancer types. 
The size of a pie chart shows the total number of motifs in a given transcription factor 
family (given in curly braces according to TFClass). The slices of a pie show the number 
of conserved binding motifs protected from any affinity change (yellow), motifs 
protected from affinity loss (magenta), and motifs protected from affinity gain (deep 
purple). 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Fold change (log2) of negative selection magnitude for mutations in DNase 
accessible subregions compared to that in the promoter and intronic segments. 
Y axis displays selection magnitude fold change (log2), or ratios between selection 
magnitudes estimated for DNase accessible regions to those for all promoter and 
intronic segments, the respective genomic control data is used in the both cases. Lower 
values of selection magnitude correspond to the stronger negative selection, thus 
negative fold change values correspond to stronger negative selection in DNase 
accessible regions. X axis displays different significantly conserved motifs (P < 0.05) for 
the set of promoter and intronic mutations. Data for affinity loss (A) and affinity gain (B) 
is presented for breast cancer (top subpanels) and lung adenocarcinoma (bottom 
subpanels). Members of FOX and NR transcription factor families are colored in blue 
and green.  
 
  
  
 
Figure 4. Procedure used to evaluate affinity change events and estimate significance of 
difference between observed and expected frequencies. 
Top panel: prediction of binding sites in cancer and control data and evaluation of 
affinity change events. Bottom panel: binding sites predictions and affinity change 
events of AP-2 motifs; an example of 2x2 contingency table used to compute Fisher's 
exact test P-value. 
  
Table 1. Examples of selection magnitude for conserved binding motifs and motifs frequently affected by somatic mutations. Selection magnitude 
estimated against two control data sets is given. Significant cases are colored by light green (protection from affinity change) and light red (frequent 
affinity change). Selected members of several transcription factor families are shown. 
  
Breast Liver Lung Adeno 
Motif Family 
Loss (vs 
genomic) 
Loss (vs 
shuffle) 
Gain (vs 
genomic) 
Gain (vs 
shuffle) 
Loss (vs 
genomic) 
Loss (vs 
shuffle) 
Gain (vs 
genomic) 
Gain (vs 
shuffle) 
Loss (vs 
genomic) 
Loss (vs 
shuffle) 
Gain (vs 
genomic) 
Gain (vs 
shuffle) 
AP2A AP-2 1.218 1.208 0.911 0.909 1.063 0.928 1.114 0.855 1.082 1.011 1.175 1.091 
AP2B AP-2 1.125 1.166 0.887 0.957 1.089 0.972 1.199 1.036 1.021 1.005 1.016 1.010 
CEBPA C/EBP-related 1.107 1.112 1.024 0.948 0.997 0.945 0.988 0.945 0.972 0.898 0.994 0.922 
CEBPB C/EBP-related 1.099 1.127 0.979 0.868 0.968 0.955 0.969 0.882 0.947 0.930 0.993 0.862 
CEBPE C/EBP-related 1.045 1.080 0.980 0.972 1.069 1.085 0.973 1.008 0.929 0.942 0.986 0.936 
CEBPG C/EBP-related 1.182 1.211 0.968 0.916 1.018 1.027 0.958 0.943 0.960 0.920 0.989 0.933 
EGR1 Ets-related 1.113 1.165 0.933 1.246 1.141 1.079 1.088 1.129 1.052 1.106 0.978 1.159 
ELF1 Ets-related 0.931 0.910 1.142 1.087 0.984 0.907 1.080 0.988 0.921 0.905 1.046 1.019 
ETS1 Ets-related 0.930 0.906 1.090 1.028 0.995 0.918 1.086 0.995 0.935 0.875 1.029 1.021 
FOXC1 Forkhead box 0.973 0.885 0.977 0.904 1.007 0.966 0.959 0.923 0.949 0.869 0.932 0.872 
FOXO1 Forkhead box 1.009 0.928 0.990 0.905 0.986 0.949 0.946 0.882 0.901 0.857 0.980 0.881 
FOXQ1 Forkhead box 0.978 0.904 0.942 0.922 0.993 0.978 0.927 0.955 1.002 0.930 0.960 0.956 
SP1 Krüppel-related 1.067 1.201 1.389 1.099 1.054 1.082 1.278 0.954 1.007 1.139 1.267 1.005 
SP2 Krüppel-related 0.996 1.112 1.132 1.158 1.038 0.980 1.114 1.041 0.949 1.017 1.083 1.083 
SP3 Krüppel-related 1.115 1.346 1.412 1.193 1.063 1.091 1.151 0.962 1.004 1.157 1.304 1.062 
ESR1_do Steroid receptors 0.838 0.688 0.815 0.636 1.047 0.860 1.017 0.819 0.9846 0.834 0.901 0.730 
ESR2_do Steroid receptors 0.880 0.746 0.852 0.609 1.033 0.866 0.999 0.743 1.0014 0.861 0.986 0.687 
 
  
Additional files are available at: 
http://autosome.ru/supplement/addfil2015_3.zip 
 
Additional file 1 (Format: PDF) 
Supplementary  Figure 1. Relative frequencies of non-coding mutation contexts in different 
cancer types.  
(top panel) Three cancer types with the largest number of mutation calls exhibit 
different mutation signatures. (bottom panel) Overall comparison of non-coding 
mutation signatures in 10 cancer types. The samples with lower numbers of total 
mutation calls display extreme contexts distributions. Cancer types are sorted by the 
total number of mutation calls. Mutations are grouped by the substitution (X > Y), the 5' 
and 3' nucleotides are shown in a lexicographical order. 
 
Additional file 2 (Format: PDF) 
Supplementary Figure 2. Agreement between shuffle and genomic control data for 
detection of conserved motifs (negative selection) and motifs frequently altered (targeted) by 
mutations (positive selection). 
X axis shows the number of motifs, stacked bars show the number of significant motifs 
passing P < 0.05 for shuffle only (green), genomic only (light blue) and both (deep blue) 
controls. Data for three cancer types are shown. Panels: (A) Affinity loss. (B) Affinity gain.  
 
Additional file 3 (Format: XSLX) 
Supplementary Table 1. Mutation counts, frequencies of mutation contexts and relative 
control sizes for different cancer types. Initial as well as the final size (after binding 
sites predictions and equalizing the mutation contexts distribution) of each control set 
is shown. 
  
  
Additional file 4 (Format: XSLX) 
Supplementary Table 2. Raw data on binding sites predictions across mutation-centered 
windows in all evaluated cancer data sets as well as the respective generated control 
data sets. 
  
Additional file 5 (Format: XSLX) 
Supplementary Table 3. Binding motifs under positive and negative selection. 
Data for separate motifs is shown, as well as aggregated data for the motifs grouped by 
family (number of significantly protected motifs is shown, family name and ID are given 
according to TFClass). 
 
Additional file 6 (Format: XSLX) 
Supplementary Table 4. Overview of DNase accessibility data analysis including 
mutation counts, motif predictions and data sources used to filter mutations in 
regulatory regions for breast cancer and lung adenocarcinoma. 
 
Additional file 7 (Format: XSLX) 
Supplementary Table 5. Binding motifs found under positive and negative selection in a 
basic test considering mutations overlapping and avoiding binding sites predictions. 
Raw data on binding sites predictions is given along with the resulting aggregated 
information for motif families. 
